Innovent Biologics, Inc. (FRA:6IB)

Innovent Biologics Ratios and Metrics

Market cap in millions EUR. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Nov 26, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	17,764	7,456	8,030	6,168	7,955	12,136
Market Cap Growth	132.85%	-7.15%	30.17%	-22.46%	-34.45%	216.45%
Enterprise Value	17,019	6,750	7,395	5,388	6,693	11,531
Last Close Price	10.30	4.36	4.50	3.84	5.10	8.05
PS Ratio	13.08	5.98	10.14	9.98	13.46	25.21
PB Ratio	10.36	4.30	5.02	4.24	5.56	11.04
P/TBV Ratio	11.47	4.40	5.04	4.25	5.57	11.04
P/FCF Ratio	103.24	175.32	-	-	-	-
P/OCF Ratio	82.28	43.78	425.78	-	-	-
EV/Sales Ratio	12.31	5.41	9.34	8.72	11.33	23.96
EV/EBITDA Ratio	111.23	2126.28	-	-	-	-
EV/FCF Ratio	98.90	158.73	-	-	-	-
Debt / Equity Ratio	0.23	0.22	0.29	0.30	0.24	0.14
Debt / EBITDA Ratio	2.54	50.93	-	-	-	-
Debt / FCF Ratio	2.33	8.81	-	-	-	-
Asset Turnover	0.52	0.45	0.33	0.27	0.30	0.40
Inventory Turnover	2.94	2.69	1.51	1.00	1.19	1.45
Quick Ratio	2.25	2.08	2.68	2.78	3.27	5.85
Current Ratio	2.61	2.35	3.00	3.29	3.79	6.37
Return on Equity (ROE)	8.43%	-0.74%	-8.84%	-20.70%	-28.56%	-14.75%
Return on Assets (ROA)	2.65%	-0.82%	-5.12%	-11.54%	-12.04%	-3.65%
Return on Capital (ROIC)	3.46%	-1.08%	-6.49%	-14.57%	-14.81%	-4.46%
Return on Capital Employed (ROCE)	5.00%	-1.60%	-9.70%	-22.20%	-20.50%	-5.40%
Earnings Yield	0.76%	-0.17%	-1.63%	-4.79%	-4.75%	-1.03%
FCF Yield	0.97%	0.57%	-1.54%	-6.19%	-5.38%	-0.82%
Buyback Yield / Dilution	-3.74%	-4.35%	-4.67%	-2.37%	-7.27%	-15.23%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.